Summary: Researchers from WUSTL have identified a compound that targets APOE in mouse brains and which protects against Alzheimer’s disease. The APOE4 genetic variant increases the risk of people developing Alzheimer’s disease. The findings offer new possible avenues of treating the disease in humans.
People who carry the APOE4 genetic variant face a substantial risk for developing Alzheimer’s disease.
Now, researchers at Washington University School of Medicine in St. Louis have identified a compound that targets the APOE protein in the brains of mice and protects against damage induced by the Alzheimer’s protein amyloid beta.
“Scientists have been interested in APOE for years but there are only a few examples where researchers have targeted it with a compound in living animals,” said senior author David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology. “Our findings indicate that APOE is not just involved in Alzheimer’s risk and disease progression, but it could potentially be a real target for treatment or prevention.”
The study is published Dec. 6 in the journal Neuron.
Alzheimer’s, which affects one in 10 people over age 65, is marked by brain plaques made of a sticky protein known as amyloid beta. The plaques start forming in the brains of Alzheimer’s patients years before the characteristic symptoms of memory loss and confusion appear. APOE4 raises the risk of Alzheimer’s partly by encouraging amyloid beta to collect into damaging plaques.
Holtzman, first author and MD/PhD student Tien-Phat Huynh, and colleagues studied mice genetically prone to develop amyloid plaques and that carry the human APOE4 genetic variant. People with APOE4 face up to 12 times the risk of developing Alzheimer’s than the general population.
The researchers targeted the APOE protein using a kind of DNA-based molecule created by co-author Tracy Cole, PhD, and others at Ionis Pharmaceuticals. The molecule – known as an antisense oligonucleotide – interferes with the instructions for building the APOE protein.
The researchers injected the compound into the fluid surrounding the brains of newborn mice. For comparison, they gave other newborn mice either saltwater or a placebo “oligo” that does not interfere with the APOE instructions. Levels of APOE protein dropped by about half in mice given the APOE compound as compared with those that received the placebo oligo or saltwater.
Two months later, the researchers gave the mice a booster dose of the treatment or the saltwater. They examined the mice’s brains at 4 months old. By this time, the brains of such mice normally would be dotted with plaques and show widespread injury.
The mice that received the APOE antisense oligos had about half as many amyloid plaques as mice given saltwater. Each plaque triggered only half as much damage to nearby neurons, an indicator that the compound had prevented some of the neurological damage that leads to Alzheimer’s disease.
While the results are encouraging, more work is needed before the compound could be evaluated in people. Healthy young people with no signs of Alzheimer’s are unlikely to be interested in taking a drug to prevent a disease that may never occur. The researchers therefore tested whether giving the APOE compound after amyloid plaques appear could prevent further changes to the brain. For most people who one day will be diagnosed with Alzheimer’s, plaques start forming in late adulthood. In these genetically modified mice, plaques first appear at about 6 weeks old.
The researchers introduced either the APOE compound or saltwater into the fluid surrounding the brains of 6-week old mice, and then examined the mice’s brains at 4 months old. They found no difference in the number of plaques or the total amount of amyloid beta between the mice that received the compound and those given just saltwater. The compound failed to reduce the amount of amyloid in the mice’s brains.
However, in the mice treated with the APOE compound, each plaque triggered only about half as much damage to the surrounding neurons, suggesting that even a late start could reduce the harm posed by amyloid beta.
“If you wanted to target APOE to affect the amyloid process, the best thing would be to start before the plaques form,” Holtzman said. “But even if you start later, you still may reduce the amount of damage caused by the plaques. Now that we have shown that it is possible to target APOE, we can start figuring out the best way to do it.”
Funding: The research was supported by National Institutes of Health, JPB Foundation, Howard Hughes Medical Institute.
Source: Judy Martin Finch – WUSTL
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is credited to Tien-Phat Huynh.
Original Research: Abstract for “Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis” by Tien-Phat V. Huynh, Fan Liao, Caroline M. Francis, Grace O. Robinson, Javier Remolina Serrano, Hong Jiang, Joseph Roh, Mary Beth Finn, Patrick M. Sullivan, Thomas J. Esparza, Floy R. Stewart, Thomas E. Mahan, Jason D. Ulrich, Tracy Cole, and David M. Holtzman in Neuron. Published online December 6 2017 doi:10.1016/j.neuron.2017.11.014
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
•ApoE has little effect on Aβ accumulation after the initial seeding stage
•Decreasing apoE once fibrils have formed leads to an increase in plaque size
•ApoE4 reduction decreases neuritic dystrophy, independent of Aβ plaque load
•ApoE-targeted therapies aiming to reduce Aβ plaques should focus on prevention
The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer disease. Previous studies suggest that reduction of apoE levels through genetic manipulation can reduce Aβ pathology. However, it is not clear how reduction of apoE levels after birth would affect amyloid deposition. We utilize an antisense oligonucleotide (ASO) to reduce apoE expression in the brains of APP/PS1-21 mice homozygous for the APOE-ε4 or APOE-ε3 allele. ASO treatment starting after birth led to a significant decrease in Aβ pathology when assessed at 4 months. Interestingly, ASO treatment starting at the onset of amyloid deposition led to an increase in Aβ plaque size and a reduction in plaque-associated neuritic dystrophy with no change in overall plaque load. These results suggest that lowering apoE levels prior to plaque deposition can strongly affect the initiation of Aβ pathology while lowering apoE after Aβ seeding modulates plaque size and toxicity.
“Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis” by Tien-Phat V. Huynh, Fan Liao, Caroline M. Francis, Grace O. Robinson, Javier Remolina Serrano, Hong Jiang, Joseph Roh, Mary Beth Finn, Patrick M. Sullivan, Thomas J. Esparza, Floy R. Stewart, Thomas E. Mahan, Jason D. Ulrich, Tracy Cole, and David M. Holtzman in Neuron. Published online December 6 2017 doi:10.1016/j.neuron.2017.11.014